Literature DB >> 11805161

Biphasic vasodilator action of troglitazone on the renal microcirculation.

Shuji Arima1, Kentaro Kohagura1, Kazuhisa Takeuchi1, Yoshihiro Taniyama1, Akira Sugawara1, Yukio Ikeda1, Michiaki Abe1, Ken Omata1, Sadayoshi Ito1.   

Abstract

Recent studies have demonstrated that thiazolidinediones, novel antidiabetic compounds that improve the insulin sensitivity, lower BP and decrease urinary protein excretion. However, neither the target vasculature nor the underlying mechanism for their actions is well understood. In this study, the action of troglitazone (Tro), a thiazolidinedione compound, on the glomerular afferent (Af-Arts) and efferent (Ef-Arts) arterioles, crucial vascular segments to the control of glomerular hemodynamics, were directly examined. Rabbit Af-Arts or Ef-Arts were microdissected from the superficial cortex and perfused at constant pressure. Increasing doses of Tro (10(-8) to 10(-5) M) were added to both the bath and lumen of preconstricted arterioles. In Af-Arts, Tro caused dose-dependent and biphasic dilation. Tro at 10(-5) M increased the diameter by 28 +/- 6% (n = 8, P < 0.01) until 20 min, with the diameter remaining at this level for 60 min, and then Tro began to dilate Af-Arts again. At 120 min, Tro at 10(-5) M further increased the diameter by 23 +/- 4% (n = 6). Disrupting the endothelium had no effect on either dilation (n = 7 or n = 5). Pretreatment with SKF 96365 (50 microM), which inhibits both voltage- and receptor-operated calcium channels, abolished the early-phase dilation without affecting the late-phase dilation; 20 or 120 min after adding Tro at 10(-5) M, the diameter increased by 4 +/- 2% (n = 7) or 28 +/- 3% (n = 6), respectively. In contrast to Af-Arts, Tro caused monophasic dilation in Ef-Arts; Tro at 10(-5) M did not cause significant dilation until 80 min, and at 120 min the diameter increased by 37 +/- 4% (n = 5). These results suggest that in the Af-Art Tro has biphasic endothelium-independent vasodilator action, which is partly mediated by an inhibition of calcium influx. This vasodilator action may play a role in the BP-lowering effect of Tro. In addition, by dilating the postglomerular Ef-Art, Tro may decrease the glomerular capillary pressure and hence the excretion of urinary protein.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11805161     DOI: 10.1681/ASN.V132342

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  9 in total

Review 1.  Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.

Authors:  Lennart Tonneijck; Marcel H A Muskiet; Mark M Smits; Erik J van Bommel; Hiddo J L Heerspink; Daniël H van Raalte; Jaap A Joles
Journal:  J Am Soc Nephrol       Date:  2017-01-31       Impact factor: 10.121

2.  The in vivo effects of the Pro12Ala PPARgamma2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank.

Authors:  G D Tan; M J Neville; E Liverani; S M Humphreys; J M Currie; L Dennis; B A Fielding; F Karpe
Journal:  Diabetologia       Date:  2005-12-17       Impact factor: 10.122

3.  Protective effects of PPARγ agonist in acute nephrotic syndrome.

Authors:  Yiqin Zuo; Hai-Chun Yang; Sebastian A Potthoff; Behzad Najafian; Valentina Kon; Li-Jun Ma; Agnes B Fogo
Journal:  Nephrol Dial Transplant       Date:  2011-05-12       Impact factor: 5.992

4.  Effects of combination PPARγ agonist and angiotensin receptor blocker on glomerulosclerosis.

Authors:  Keizo Matsushita; Hai-Chun Yang; Manu M Mysore; Jianyong Zhong; Yu Shyr; Li-Jun Ma; Agnes B Fogo
Journal:  Lab Invest       Date:  2016-03-21       Impact factor: 5.662

Review 5.  Nitric oxide in the normal kidney and in patients with diabetic nephropathy.

Authors:  Paolo Tessari
Journal:  J Nephrol       Date:  2014-09-13       Impact factor: 3.902

Review 6.  PPARγ agonist beyond glucose lowering effect.

Authors:  Akira Sugawara; Akira Uruno; Masataka Kudo; Ken Matsuda; Chul Woo Yang; Sadayoshi Ito
Journal:  Korean J Intern Med       Date:  2011-03-02       Impact factor: 2.884

Review 7.  Pathogenesis and novel treatment from the mouse model of type 2 diabetic nephropathy.

Authors:  Masako Furukawa; Tomohito Gohda; Mitsuo Tanimoto; Yasuhiko Tomino
Journal:  ScientificWorldJournal       Date:  2013-04-24

Review 8.  Maintenance of Kidney Metabolic Homeostasis by PPAR Gamma.

Authors:  Patricia Corrales; Adriana Izquierdo-Lahuerta; Gema Medina-Gómez
Journal:  Int J Mol Sci       Date:  2018-07-16       Impact factor: 5.923

9.  Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus.

Authors:  Kyung-Soo Kim; Sangmo Hong; Hong-Yup Ahn; Cheol-Young Park
Journal:  Diabetes Ther       Date:  2020-10-24       Impact factor: 2.945

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.